Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) Receives Average Rating of “Hold” from Brokerages
Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have been assigned an average recommendation of “Hold” from the twenty-six ratings firms that are currently covering the firm. One research analyst has rated the stock with a sell recommendation, thirteen have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $486.79.
Several equities research analysts recently commented on the company. Leerink Swann set a $511.00 target price on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, August 6th. RBC Capital Markets reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Saturday, August 6th. Robert W. Baird reaffirmed a “neutral” rating and set a $448.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, September 23rd. Canaccord Genuity reaffirmed a “hold” rating and set a $450.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, August 5th. Finally, Roth Capital reaffirmed a “buy” rating and set a $520.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 4th.
In other news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $425.00, for a total value of $903,125.00. Following the sale, the director now directly owns 15,125 shares of the company’s stock, valued at $6,428,125. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.40% of the stock is currently owned by insiders.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/regeneron-pharmaceuticals-inc-nasdaqregn-receives-average-rating-of-hold-from-brokerages.html
Large investors have recently made changes to their positions in the company. Nikko Asset Management Americas Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $216,000. NN Investment Partners Holdings N.V. purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $1,477,000. Shufro Rose & Co. LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $1,203,000. Bessemer Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 171 shares during the last quarter. Finally, C M Bidwell & Associates Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $3,612,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 1.14% during midday trading on Monday, hitting $394.50. The stock had a trading volume of 506,967 shares. Regeneron Pharmaceuticals has a 52 week low of $329.09 and a 52 week high of $592.59. The company’s 50 day moving average is $401.81 and its 200 day moving average is $391.84. The firm has a market cap of $41.28 billion, a P/E ratio of 61.54 and a beta of 1.31.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The company earned $1.21 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same period last year, the company earned $2.89 earnings per share. The firm’s revenue was up 21.4% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals will post $11.02 earnings per share for the current fiscal year.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.